(2,5-Dioxopyrrolidin-1-yl) [3-(3-methoxybutoxy)-2-[(3-methoxy-3-methylbutoxy)methyl]-3-methylpentyl] carbonate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (2,5-Dioxopyrrolidin-1-yl) [3-(3-methoxybutoxy)-2-[(3-methoxy-3-methylbutoxy)methyl]-3-methylpentyl] carbonate
• 英文别名: (2,5-dioxopyrrolidin-1-yl) [3-(3-methoxybutoxy)-2-[(3-methoxy-3-methylbutoxy)methyl]-3-methylpentyl] carbonate
• 化学式: C₂₃H₄₁NO₉
• 分子量: 475.6
• InChiKey: SATAQEKNOZJVJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  33
• 可旋转键数：
  18
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  110
• 氢给体数：
  0
• 氢受体数：
  9

文献信息

• [EN] NUCLEIC ACID MODULATORS OF ALPHA2BETA1<br/>[FR] MODULATEURS DES ACIDES NUCLÉIQUES DE &Agr;2&Bgr;1
  申请人：NOVAMEDICA LTD LIABILITY COMPANY

  公开号：WO2014066084A1

  公开（公告）日：2014-05-01

  Compositions are provided comprising the nucleic acid ligand and/or a modulator as well as methods of using these agents and compositions in treating α2β1-mediated diseases and disorders. Also provided is a pharmacologic system comprising a nucleic acid ligand that binds to and regulates the activity of the integrin α2β1 protein. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize its pharmacologic effect and thereby restore α2β1 function.